Next-Generation SGLT2 Inhibitors: Innovations and Clinical Perspectives

Dana Movila, Daniel Duda Seiman, Simona Ruxanda Dragan · 2025

Read Next-Generation SGLT2 Inhibitors: Innovations and Clinical Perspectives by Dana Movila, Daniel Duda Seiman, Simona Ruxanda Dragan (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12839024.txt.

Description

A diabetes drug class that spills sugar into urine has outgrown its first job: it now guards the heart and kidneys too. Dana Movila, Daniel Duda Seiman, and Simona Ruxanda Dragan survey the class's next wave in 2025. The first wave's twin stars anchor the tale.

New forms sharpen aim at the sugar gate, stretch how long each dose lasts, or block a sister gate as well, for a dual hit. Dose plans bend to the patient: weak hearts with full squeeze, worn kidneys, and more. The review weighs trial proof for each twist and flags where proof is thin. The class's arc, from sugar aid to organ guard, makes it a model of how a drug can be reborn.

Catalog record

CREATORDana Movila, Daniel Duda Seiman, Simona Ruxanda Dragan
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE49 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC12839024

Browse the full library · About the Tower of Babel